This site is intended only for Australian Healthcare Professionals

Search

Menu

Close

Sign In or RegisterLog Out Our medicinesTherapy areasExplore contentExplore contentEventsVideosMaterialsLet’s connectLet's ConnectContact usAsk a questionPfizer Medical InformationStay connectedSuggest a topicPharmacy HubKnowledge Hub

Menu

Close

AboutStudy Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 36-month overall efficacy1L 36-month CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementDosingTherapy managementResourcesEventsMaterialsVideos
Prescribing InformationPatient InformationIndicationPatient Site
A once-daily oral treatment with flexible dosing to manage adverse reactions1

For special warnings and precautions for use, please see the LORVIQUA Product Information.

  • LORVIQUA should be swallowed whole, with or without food—never chewed, crushed, or split1
  • LORVIQUA is contraindicated in patients taking strong CYP3A inducers concomitantly* and in those with hypersensitivity to LORVIQUA or any of the excipients in LORVIQUA tablets1
  • For patients taking LORVIQUA, alternative concomitant medicinal products with less potential to inhibit CYP3A should be considered1,*
  • Patients should avoid grapefruit products while taking LORVIQUA1
  • There are specific recommendations for dose modifications related to particular ARs1
*Please refer to the LORVIQUA Product Information for recommendations regarding the use of CYP3A inducers and CYP3A inhibitors.AR=adverse reaction; CYP3A=cytochrome P450 3A.ReferencesReference:LORVIQUA Product Information.Dosing & Therapy Management
LORVIQUA safety profile
 Review the safety Loading
LORVIQUA efficacy
 Discover the data Loading

Before prescribing, please review Product Information available here.

▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information.​
Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

PBS Information: Authority required. Locally advanced or metastatic ALK+ non-small cell lung cancer.​
Refer to PBS Schedule for full authority information.​

LORVIQUA® is a registered trademark of Pfizer.

PP-LOR-AUS-0073 September 2023
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about Pfizer medicines and vaccines.

Sign inRegisterAccountSign Out

The site is intended for Australian healthcare professionals.

 

©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.

 

PP-UNP-AUS-0551 12/23.

You are now leaving Pfizer
You are leaving PfizerPro.
You may be directed to a third-party website.
Please note third-party websites are not controlled by Pfizer or subject to our privacy policy.
 
PP-UNP-AUS-0551 12/23.